Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04859296 · ClinicalTrials.gov registry record · Phase 1

AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)

A Phase 1 study of Pain and Abuse, Drug, sponsored by University of California, Los Angeles.

Active
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT04859296: Active Phase 1 study of Pain and Abuse, Drug, sponsored by University of California, Los Angeles.

NCT04859296 is a Phase 1 study of Pain and Abuse, Drug that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 20 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04859296, a Phase 1 study of Pain and Abuse, Drug, is active but no longer recruiting, sponsored by University of California, Los Angeles.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This study will assess the analgesic, appetite-stimulating, and subjective effects of cannabigerol (CBG) alone and in combination with THC.

Primary Outcome

Pain threshold and pain tolerance assessed with the Cold Pressor Test - time to report first feeling pain (0-180 seconds) and remove the hand from the cold water (0-180 seconds). Increased duration means increased pain tolerance and pain threshold.

Conditions Studied

Pain Abuse, Drug Appetite Loss

Interventions

  • DRUG Placebo
  • DRUG Low THC
  • DRUG High THC
  • DRUG Low CBG
  • DRUG High CBG

Study Locations (1)

California

  • University of California, Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-02-15
Est. Completion 2026-12-04
Phase Phase 1
University of California, Los Angeles

897 total trials

What the registry record for NCT04859296 still lists

NCT04859296 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (93% lower).

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT04859296 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04859296 about?

NCT04859296 is a clinical study titled "AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)". This study will assess the analgesic, appetite-stimulating, and subjective effects of cannabigerol (CBG) alone and in combination with THC.

What is the current status of trial NCT04859296?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-02-15. Estimated completion is 2026-12-04.

What conditions does trial NCT04859296 study?

This clinical trial studies the following conditions: Pain, Abuse, Drug, Appetite Loss.

What interventions are being tested in trial NCT04859296?

The interventions under investigation include: Placebo (DRUG), Low THC (DRUG), High THC (DRUG), Low CBG (DRUG), High CBG (DRUG).

Who is sponsoring clinical trial NCT04859296?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04859296 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04859296's enrollment target sits among peer trials

20 338th of 374 higher than 29 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04859296, the US trial registry maintained by the National Library of Medicine. NCT04859296 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.